abstract |
Disclosed is a pharmaceutical composition having improved solubility characteristics of a poorly water-soluble protein kinase inhibitor typified by lapatinib. A stable amorphous hybrid nanoparticle of an inhibitor and at least one polymeric stabilizing matrix-forming component, optionally further comprising at least one pharmaceutically acceptable solubilizer. A pharmaceutical composition wherein the inhibitor is present in an amount of about 10% to about 70% by weight of the amorphous nanoparticles and the polymeric stabilizing matrix-forming component is hydroxypropylcellulose. Composition. [Selection figure] None |